Safe use of insulin regular concentrated (500 units/ml) in severe insulin resistance
|
|
- Philippa Boyd
- 6 years ago
- Views:
Transcription
1 Safe use of insulin regular concentrated (500 units/ml) in severe insulin resistance Jodie S. Gee, Pharm.D., BCACP, CDE Clinical Pharmacy Specialist-Ambulatory Care Harris Health System
2 Objectives To be able to identify appropriate patients for U-500 insulin therapy Distinguish place in therapy for U-500 insulin Discuss safety recommendations for U-500 insulin Counsel patients on safe use of U-500 Formulate a therapeutic care plan for a patient using U-500
3 Patient Case Chief compliant: My sugars are so high and I m on so much insulin! TH is a 47 y/o Caucasian female who presents to the clinic for evaluation of blood sugars. She reports compliance with her medication regimen Past medical history: Type 2 diabetes (diagnosed in 2000) Hypertension Insomnia Depression Social history: Denies smoking and alcohol
4 Patient case Allergies: NKDA Medications Insulin detemir (Levemir flextouch ) 120 units SC q 12 hours Insulin aspart (Novolog flexpen ) 80 units SC TID AC Metformin 1000 mg BID Atorvastatin 40 mg daily Lisinopril 10 mg daily Sertraline 25 mg daily
5 Patient case Vitals Blood pressure Pulse Height Weight BMI 119/ lbs (124 kg) 47 kg/m 2 Labs (9/15/17) Hemoglobin A1c (%) (H)
6 Patient case Date Fasting Before lunch Before dinner Bedtime 9/ / / / / / / / / / / /16 271
7 Clinical Question What would you do with this patient?
8 Background- Severe insulin resistance Severe insulin resistance Total daily insulin requirement > 200 units/day > 2 units/kg/day Note: typical human pancreas secretes ~ units/day Metabolic disorders Obesity Hypertension Hyperlipidemia Cardiovascular disease Non-alcoholic fatty liver disease (NAFLD) Barnosky AB et al. Postgraduate medicine. 2016; 128 (4):
9 Background- Severe insulin resistance Etiology Type 2 diabetes mellitus with obesity Protease inhibitor use (lipodystrophy) Insulin receptor defects (Type A insulin resistance syndrome) Insulin receptor auto-antibodies (Type B insulin resistance syndrome) High dose glucocorticoids Barnosky AB et al. Postgraduate medicine. 2016; 128 (4):
10 Treatment- Severe insulin resistance Conventional insulin U-100 (100 units/ml) Insulin syringes max 100 units/injection Insulin pen devices max units/injection Increased number of injections Several injections per dose Large volumes injected Poor absorption Suboptimal glycemic control Poor compliance Injection discomfort Leakage Barnosky AB et al. Postgraduate medicine. 2016; 128(4): Lane WS et al. Endocr Pract. 2009; 15(1): 71-79
11 Treatment- Severe insulin resistance Concentrated insulin regular U-500 (500 units/ml) 5 times more concentrated than conventional U-100 insulin 1 ml of U-100 = 100 units 1 ml of U-500 = 500 units Decreased volume with each injection 1/5 volume with U-500 than U-100 Decreased number of injections Improved injection comfort Not necessarily a more powerful or stronger insulin Liquid is reduced with U-500 insulin compared to U-100 Barnosky AB et al. Postgraduate medicine. 2016; 128(4): Lane WS et al. Endocr Pract. 2009; 15(1): 71-79
12 Treatment- Severe insulin resistance U-100 insulin (100 units/ml) vs Concentrated insulin regular U-500 (500 units/ml) Same # of insulin particles/units, less liquid U-100 insulin U-500 insulin
13 Overview of insulin regular concentrated (U-500)
14 Pharmacokinetics- U-500 Insulin Concentrating the insulin alters pharmacodynamics and pharmacokinetics Works as both basal and bolus insulin Action profile similar to NPH insulin Onset: minutes Peak: 4 hours Duration: hours (8 hours in some patients) Typically used as monotherapy Limited data on combining U-500 with other insulins Higher risk of hypoglycemia Barnosky AB et al. Postgraduate medicine. 2016; 128(4): Humulin R U-500 (package insert). Indianapolis, IN: Eli Lilly and Co.; 2016 Garg R et al. Diabetes Metab Res Rev. 2007; 23:
15 Safety concerns with U-500 insulin- Institute for Safe Medication Practices (ISMP) Dose errors (overdose) Utilizing incorrect syringes (U-100 syringes vs tuberculin or U-500 syringes) Accidentally giving 5 times the intended dose Dose conversion/calculation errors (providers and dispensing pharmacists) Dispensing errors Confusing Regular insulin U-100 with Regular insulin U-500 Severe hypoglycemia
16 Selecting patients for U-500 insulin therapy Total daily dose of insulin > 200 units/day or > 2 units/kg/day Type 2 diabetes mellitus with obesity Protease inhibitor use (lipodystrophy) Insulin receptor defects (Type A insulin resistance syndrome) Insulin receptor auto-antibodies (Type B insulin resistance syndrome) High dose glucocorticoids Gestational diabetes with severe insulin resistance Adequate health literacy Compliance with clinic follow-up appointments Lane WS et al. Endocr Pract. 2009; 15(1): 71-79
17 Ziesmer et al. Objective: Evaluate use of U-500 in insulin resistant patients (Type 2 diabetes) previously on U-100 insulin Methods Retrospective chart review (N=66) Follow up > 6 months Data collected: total daily insulin dose, HbA1c, body weight, lipids, episodes of severe hypoglycemia VA North Texas Health Care System Dallas Primary outcome: Change in HbA1c Secondary outcome: Changes in insulin dose, body weight, lipids, frequency of severe hypoglycemia Ziesmer AE et al. Endocr Pract. 2012; 18:34-38
18 Ziesmer et al. Safety- Hospital U-500 Policy Ziesmer AE et al. Endocr Pract. 2012; 18:34-38
19 Ziesmer et al. Safety- U-500 insulin patient contract Ziesmer AE et al. Endocr Pract. 2012; 18:34-38
20 Ziesmer AE et al. Endocr Pract. 2012; 18:34-38 Ziesmer et al. Results Baseline (U-100) End of study (U-500) P value HbA1c (%) <0.001 Insulin (units/day) Weight (kg) BMI (kg/m 2 ) Conclusions U-500 can be safely and effectively used when a strict protocol and close patient monitoring is utilized
21 Initiating U-500 insulin Calculate total daily dose (TDD) of insulin (Basal + bolus) HbA1c >10% ->Increase TDD by 10% HbA1c 8-10% -> Same TDD HbA1c <8% -> Decrease TDD by 10% TDD = units TDD = units TDD > 600 units Two daily injections (60/40) OR Three daily injections (40/30/30, 45/35/20, 40/40/20, 33/33/33)** Three daily injections** OR Four daily injections (30/30/30/10) OR Insulin pump Four daily injections (30/30/30/10- preferred, 25/25/25/25) OR Insulin pump Lane WS et al. Endocr Pract. 2009; 15(1): Reutrakal et al. J Diabetes Sci Technol. 2012; 6(2):
22 Initiating U-500 insulin Injections always given pre-meal Example of dose timings: Two daily injections: 8 am and 6 pm Three daily injections: 8 am, 12 pm, 6 pm Four daily injections: 8 am, 12 pm, 5 pm, 10 pm Discontinue prior insulin therapy (ie. Basal and bolus insulins) Ensure that patient and family members are properly educated Lane WS et al. Endocr Pract. 2009; 15(1): Reutrakal et al. J Diabetes Sci Technol. 2012; 6(2):
23 Safety Safest use of U-500 U-500 syringes Each line is 5 units No conversion necessary U-500 pen No conversion necessary Tuberculin syringes Dosed in ml instead of units Use of U-100 syringes with U-500 (DANGER! CAUTION!) Conversion is needed Potential for errors by providers and pharmacy (miscalculation) Potential for overdose by patients Not the safest option Must divide original dose by 5 to get the volume patient is to draw up May confuse the patients Recommend using terminology on Rx s and instructions Draw up X units volume in a U-100 syringe three times daily before meals
24 Syringes - Dose Conversion Actual dose of U-500 (Dose calculated based on patient s total daily dose) Volume in ml (ie. Tuberculin syringe) (Actual dose 500) Volume marking on U- 100 syringe (patient will draw this up in U-100 syringe) (Actual dose 5) 50 units 0.1 ml 10 units 75 units 0.15 ml 15 units 100 units 0.2 ml 20 units 125 units 0.25 ml 25 units 150 units 0.3 ml 30 units 175 units 0.35 ml 35 units 200 units 0.4 ml 40 units 225 units 0.45 ml 45 units 250 units 0.5 ml 50 units 275 units 0.55 ml 55 units
25 Syringes U-500 syringe - Green Tuberculin syringe
26
27 Titration Self monitored glucose reading target Insulin dose to adjust Self monitored glucose value Dose titration Fasting/Prebreakfast Pre-lunch Pre-dinner Pre-dinner Pre-breakfast Pre-lunch <70-10% No change % % > % Obtain at least 3 days worth of glucose readings Titrate to the nearest 5-unit increment Hood et al. Endocr Pract. 2015; 21:
28 Safety- Implementation at Harris Health System Team approach Pharmacy (Clinical pharmacy specialists, dispensing pharmacists, pharmacy supervisors) Clinical pharmacy specialists Inservice pharmacy personnel and physicians/mid-level providers Perform U-500 education on all patients initiated Physicians/mid-level providers Diabetic educators Harris Health Protocol Clinical pharmacy must be consulted by physicians/mid-level providers upon initiating U-500 All dose calculations double checked by a second provider All education on U-500 completed at clinical pharmacist visit Patient not to start taking U-500 until clinical pharmacist visit Dispensing pharmacy (Harris Health pharmacies) pages MD/clinical pharmacist to verify doses on all new U-500 Rx s Use U-500 syringe for Rx s filled at Harris Health pharmacies Use U-500 pen for Rx s filled at outside retail pharmacies
29 Safety- Considerations for Implementation Team approach Education! Education! Education! Strict protocol/process implementation Provider education and reinforcement Patient not to start until after education visit Patient to demonstrate proficiency at education visit with teach back method Consider a patient contract Safety! All dose calculations double checked by 2 providers Try to use U-500 or tuberculin syringes or U-500 pen
30 Patient Counseling Patient education is VERY IMPORTANT! Dosing and use of proper syringes Overdoses with improper use of U-100 syringes!!!!!! Administration 30 minutes before meals Hold dose if skipping meals! Patients should check their blood sugars before every meal and at bedtime Hypoglycemia signs, symptoms, treatment Rule of 15 No self-titration!!!!! Must bring meter and log to every clinic appointment
31 Patient case - Revisited
32 Patient Case- Revisited Chief compliant: My sugars are so high and I m on so much insulin! TH is a 47 y/o Caucasian female who presents to the clinic for evaluation of blood sugars. Past medical history: Type 2 diabetes (diagnosed in 2000) Hypertension Insomnia Depression Social history: Denies smoking and alcohol
33 Patient case Date Fasting Before lunch Before dinner Bedtime 9/ / / / / / / / / / / /16 271
34 Patient case Allergies: NKDA Medications Insulin detemir (Levemir flextouch ) 120 units SC q 12 hours Insulin aspart (Novolog flexpen ) 80 units SC TID AC Metformin 1000 mg BID Atorvastatin 40 mg daily Lisinopril 10 mg daily Sertraline 25 mg daily Patient reports eating 3 meals per day
35 Initiating U-500 insulin Calculate total daily dose (TDD) of insulin (Basal + bolus) HbA1c >10% ->Increase TDD by 10% HbA1c 8-10% -> Same TDD HbA1c <8% -> Decrease TDD by 10% TDD = units TDD = units TDD > 600 units Two daily injections (60/40) OR Three daily injections (40/30/30, 45/35/20, 40/40/20, 33/33/33)** Three daily injections** OR Four daily injections (30/30/30/10) OR Insulin pump Four daily injections (30/30/30/10- preferred, 25/25/25/25) OR Insulin pump Lane WS et al. Endocr Pract. 2009; 15(1): Reutrakal et al. J Diabetes Sci Technol. 2012; 6(2):
36 Syringes - Dose Conversion Actual dose of U-500 (Dose calculated based on patient s total daily dose) Volume in ml (ie. Tuberculin syringe) (Actual dose 500) Volume marking on U- 100 syringe (patient will draw this up in U-100 syringe) (Actual dose 5) 50 units 0.1 ml 10 units 75 units 0.15 ml 15 units 100 units 0.2 ml 20 units 125 units 0.25 ml 25 units 150 units 0.3 ml 30 units 175 units 0.35 ml 35 units 200 units 0.4 ml 40 units 225 units 0.45 ml 45 units 250 units 0.5 ml 50 units 275 units 0.55 ml 55 units
37 Case Step 1: Calculate total daily dose of insulin Insulin detemir (Levemir flextouch ) 120 units SC q 12 hours Insulin aspart (Novolog flexpen ) 80 units SC TID AC Total daily dose = 480 units Step 2: Determine dose frequency Total daily dose = units TID dosing (33/33/33) depending on patient s meal pattern Total daily dose = 480 units 3 = 160 units three times daily before meals Step 3: Choose syringe and convert dosing U-500 syringe/pen - No conversion necessary 160 units three times daily before meals Tuberculin syringe Calculated dose units 500 = 0.32 ml ~ 0.3 ml three times daily before meals U-100 syringe (CAUTION) Calculated dose units 5 = 32 units volume in a U-100 syringe
38 Patient case Follow-up 3 weeks later Date Fasting Before lunch Before dinner Bedtime 10/ / / / / / / HbA1c 3 months later = 7.6
39 Future implications Other concentrated insulins (glargine U-300, degludec U-200, lispro U-200) Better absorption Less variability Safer: Only available in insulin pens More expensive U-400 (BIOD-531) Phase 3 clinical trials Faster onset Shorter duration Ovalle F et al. Curr Med Res Opin. 2018; DOI: /
40 Cost U-500 vial - $0.14/unit Ovalle F et al. Curr Med Res Opin. 2018; DOI: /
41 References Barnosky A, Shah L, Meah F, et al. Postgraduate medicine. 2016; 128(4): Lane WS, Cochran EK, Jackson JA, et al. Endocr Pract. 2009; 15(1): Garg R, Johnston V, McNally PG, et al. Diabetes Metab Res Rev. 2007; 23: Humulin R U-500 (package insert). Indianapolis, IN: Eli Lilly and Co.; 2016 Ziesmer AE, Kelly KC, Guerra PA, et al. Endocr Pract. 2012; 18: Reutrakul S, Wroblewski K, Brown RL. J Diabetes Sci Technol. 2012; 6(2): Hood RC, Arakaki RF, Wysham C, et al. Endocr Pract. 2015; 21: Ovalle F, Segal AR, Anderson JE, et al. Curr Med Res Opin. 2018; DOI: /
42 Safe use of insulin regular concentrated (500 units/ml) in severe insulin resistance Jodie S. Gee, Pharm.D., BCACP, CDE Clinical Pharmacy Specialist-Ambulatory Care Harris Health System
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationLearning Objectives. Are you ready for more insulin formulations?
Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations
More informationThese Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP
These Aren t Your Average Rookies: A Primer on New and Emerging Insulins Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP Disclosures Eli Lilly & Company: Advisory board member Boehringer Ingelheim: Advisory
More information5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives
Insulin Update: New and Emerging Insulins Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Disclosures to
More informationComplete this CE activity online at ProCE.com/InsulinPart2
Complete this CE activity online at ProCE.com/InsulinPart2 Case 1: A 67 year old male with T2DM History and Presentation John is a 67 year old retiree who has been visiting your pharmacy/clinic for over
More informationU-500 Insulin: Not for Ordinary Use
Page 1 of 7 U-500 Insulin: Not for Ordinary Use Adam Clark, PharmD, BCPS Medical Clinic Pharmacist Gainesville, Florida 5/20/2010 US Pharm. 2010;35(5)(Diabetes suppl):14-17. If not already seeing them,
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationDiabetes Head to Toe May 31, 2017
Innovations in Insulin Joanne Reid RN CDE jmreid@gbhs.on.ca Danielle Benedict RPh Outline Setting the stage Insulin as pancreas replacement therapy Commonly used insulins New insulins Case Studies Dosing
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationObjectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17
Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors
More information9/16/2013. No Conflict of Interest to Disclose
Catie Prinzing MSN, APRN, Clinical Nurse Specialist September 27, 2013 No Conflict of Interest to Disclose List key concepts to determining patient insulin doses during transitions in care Identify 5 points
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationFaculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
More information4/2/2018. Human U-500 insulin Learning Objectives. Dr. Ken Cathcart FACE
Human U-500 insulin 2018 Dr. Ken Cathcart FACE Learning Objectives Participants will be able to identify when it is appropriate to use U500 insulin Participants will be able to state how to determine a
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationMore than 25.8 million children
Evaluating the Effect of U-500 Insulin Therapy on Glycemic Control in Veterans With Type 2 Diabetes Joseph A. Granata, 1 Ann D. Nawarskas, 1,2 Nina D. Resch, 1,2 and Justina M. Vigil 1,2 IN BRIEF This
More informationConcentrated Insulin & Patient Management THE QUALITY CENTER PATIENT SAFETY ORGANIZATION FEBRUARY 27, 2018
Concentrated Insulin & Patient Management THE QUALITY CENTER PATIENT SAFETY ORGANIZATION FEBRUARY 27, 2018 1 Today s Agenda 1. Introduction to concentrated insulin 2. Best practices for management of concentrated
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationADMELOG, NOVOLIN, NOVOLOG, and FIASP
ADMELOG, NOVOLIN, NOVOLOG, and FIASP Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationFinding Ways Around High Dose Insulin Requirements: U-500 Insulin, Weight Loss, and Future Therapies
Finding Ways Around High Dose Insulin Requirements: U-500 Insulin, Weight Loss, and Future Therapies Elaine K. Cochran, MSN, CRNP, BC-ADM National Institute of Diabetes and Digestive and Kidney Diseases
More informationDisclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2
Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director
More informationInpatient Glycemic Management:
Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi
More informationType I Type II Insulin Resistance
Insulin An aqueous hormonal solution made in the pancreas. Affects metabolism by allowing glucose to leave the blood and enter the body cells, preventing hyperglycemia. It is measured in units, e.g. 100
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationBasal Insulin Drug Class Prior Authorization Protocol
Basal Insulin Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationProviding Stability to an Unstable Disease
Basal Insulin Therapy Providing Stability to an Unstable Disease Thomas A. Hughes, M.D. Professor of Medicine - Retired Division of Endocrinology, Metabolism, and Diabetes University of Tennessee Health
More informationLantus levemir conversion
Lantus levemir conversion Search Learn about starting insulin-naïve patients with type 2 diabetes on Levemir. Read Important Safety & Prescribing Info on the HCP Website. Lantus and Levemir have a variety
More informationStarting and Helping People with Type 2 Diabetes on Insulin
Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationModule 5. Understanding Insulin Therapy
Module 5. Understanding Insulin Therapy EDUCATIONAL OBJECTIVES Upon completion of this activity, participants will be better able to: 1. Define the basic physiologic concept of basal-bolus insulin; 2.
More informationShort-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins
Recommended Insulin Products This guideline states the Gloucestershire Joint Formulary recommended, first choice insulin products. The intention is to support the choice of treatment for new patients,
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More information8/13/2016. Insulin Basics. Rapid-Acting Insulin Analogs. Current Insulin Products and Pens. Basal Insulin Analogs. History of Insulin Therapy
Insulin Basics Anabolic hormone involved in metabolism Following carbohydrate ingestion insulin release is stimulated Suppresses hepatic glucose production Stimulates peripheral glucose uptake Commercially-available
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationNph insulin conversion to lantus
Nph insulin conversion to lantus Search 26-2-2003 RESPONSE FROM AVENTIS. We appreciate the opportunity to respond to Dr. Grajower s request for information regarding Lantus ( insulin glargine [rdna origin.
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationDrug Effectiveness Review Project Summary Report Long acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationFor patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH
For patients uncontrolled on multiple daily injections of insulin A quick-start guide for your practice Dosing guidance 1,* V-Go: 3 options 1 For initiating V-Go in patients switching from MDI The majority
More informationDrug Use Criteria: Exogenous Insulin Products
Texas Vendor Program Use Criteria: Exogenous Products Publication History 1. Developed June 2017. Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationImproving Inpatient Diabetes Care: Focus on Safe Use of Anti-diabetic Therapies
Improving Inpatient Diabetes Care: Focus on Safe Use of Anti-diabetic Therapies Leigh Briscoe-Dwyer, PharmD, BCPS, FASHP Chief Pharmacy and Medication Safety Officer North Shore Long Island Jewish Health
More informationAll Things Insulin: Dosing, Monitoring, Titrating, Transitioning
All Things Insulin: Dosing, Monitoring, Titrating, Transitioning Target Audience: Pharmacists ACPE#: 0202-0000-18-052-L01-P Activity Type: Application-based Disclosures Stuart Haines declares that he has
More informationDisclosures. Learning Objectives 4/26/2017
Implementation of a quality improvement initiative to ensure the safe transition from prior-to-admission concentrated insulins to a formulary insulin regimen ERICA J. RHEIN, PHARMD PGY1 PHARMACY PRACTICE
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationThe New Age of Insulin: Exploring the Latest Trends in Insulin Therapy. The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy
The New Age of Insulin: Exploring the Latest Trends in Insulin Therapy Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Director of Experiential Education Associate Professor of Pharmacy Practice Midwestern
More informationMANAGEMENT OF TYPE 1 DIABETES MELLITUS
MANAGEMENT OF TYPE 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationLantus to levemir conversion
Lantus to levemir conversion The Borg System is 100 % Lantus to levemir conversion 16-6-2005 Ask the Expert on... Lantus Conversion. Karen Shapiro, PharmD, BCPS. Disclosures. June 16, 2005. Question. Would
More informationThe importance of continuous glucose monitoring when transitioning a patient from insulin detemir to U-500R
Diabetes Management The importance of continuous glucose monitoring when transitioning a patient from insulin detemir to U-500R Connie A Valdez* 1,2, Leah Fitzgerald 1,2 & Sarah Ziherl Hormachea 2 ABSTRACT
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationLEVEMIR (insulin detemir) subcutaneous solution LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector
LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationINSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.
INSULIN OVERVIEW Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro Humalog 15-30 min 30-90 min 3-5 hrs aspart glulisine Short-Acting Regular insulin NovoLog Apidra
More informationCHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia
CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia Javier Carrasco, MD, PhD Juan Ramón Jiménez Hospital University of Huelva, Spain Case Study: Medical and Social History A 60 years old female
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationDiabetes Meds Update Disclaimer and Important Info. Objectives. Page 1. Copyright , Diabetes Education Services
Diabetes Meds Update 2016 Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Disclaimer and Important Info This content is for educational purposes only. Please see Package
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationJournal Club September 29, Vanessa AKIKI PGYlII Internal Medicine
Journal Club September 29, 2017 Vanessa AKIKI PGYlII Internal Medicine AUBMC 2017 Case Presentation 41-year-old man who was diagnosed with type 1 diabetes 21 years ago presents to your clinic. He believes
More informationBRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH
Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,
More informationTechnician Tutorial: Dispensing Insulin and Other Injectable Meds
(Page 1 of 6) Technician Tutorial: Dispensing Insulin and Other Injectable Meds Insulin is a hormone secreted by the pancreas. It helps the body use glucose as an energy source. Insulin acts like a key
More informationLearning Objectives. Perioperative SWEET Success
Perioperative SWEET Success PERIOPERATIVE SWEET SUCCESS PRESENTED BY: KENDRA MARTIN, RN, BSN, CDE JENNIFER SIMPSON, RN, BC-ADM, MSN, CNS Disclosure to Participants Notice of Requirements For Successful
More informationCase Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus
Case Reports in Pediatrics Volume 2013, Article ID 703925, 4 pages http://dx.doi.org/10.1155/2013/703925 Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes
More informationDiana McNeill MD, FACP Professor of Medicine Duke University Medical Center. Disclosures
Insulin Therapy in Diabetes So Many Choices Diana McNeill MD, FACP Professor of Medicine Duke University Medical Center Disclosures Mytonomy-consultant Quantia webinars Acknowledgements: Dr. Sue Kirkman-UNC-
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More information8/21/2017 UNRAVELING THE CROWED INSULIN SCENE. A Practical Overview of Insulin Focusing on New Insulin Preparations
UNRAVELING THE CROWED INSULIN SCENE A Practical Overview of Insulin Focusing on New Insulin Preparations Patricia Garnica MS, ANP-BC, CDE, CDTC North Shore University Hospital, Manhasset, N.Y. October
More informationInsulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology
Insulin Basics Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology Disclosures Speakers Bureau for Sanofi, Astra Zeneca, Janssen, Boehringer-Ingelheim Objectives Discuss
More informationDiabetic medications
Diabetic medications Overview May 2018 List of medications ORAL MEDICATIONS o Metformin o Glipizide INJECTABLE MEDICATIONS o o o Tresiba (insulin degludec) Levemir (insulin detemir) NovoLog o NovoLog 70/30
More informationBasal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January
Basal-Bolus Insulin Therapy Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January 18 2018 Terminology No longer using the term diabetic. Diabetes does not define people. People with diabetes are individuals
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationBasal Bolus Insulin Therapy Frequently Asked Questions
1. What is Basal Bolus Insulin Therapy (BBIT)? 2. What evidence supports the use of subcutaneous Basal Bolus Insulin Therapy? 3. Does Basal Bolus Insulin Therapy apply to all patients? 4. What s wrong
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationNovel Formulations to Modify Mealtime Insulin Kinetics
Novel Formulations to Modify Mealtime Insulin Kinetics Alan Krasner, Roderike Pohl, Patrick Simms, Philip Pichotta, Robert Hauser, Errol De Souza Biodel, Inc. Danbury, CT Disclosure All authors are employees
More informationDiabetes: What You Need to Know
UW MEDICINE PATIENT EDUCATION Diabetes: What You Need to Know Discharge review before you leave the hospital We want to be sure that we explained your diabetes instructions well, so that you know how to
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationImportant Stuff. Basal Bolus What Adjustments? Pt weighs 80kg
Diabetes Boot Camp Class 4 Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Special Insulin and Pattern Management Diabetes Education Services 1998-2015. All rights
More informationManagement of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth
Management of Diabetes New Concepts New Devices New Medications Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth Objectives: At the end of this lecture, the learner will
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationInsulin Cases: Inpatient and Outpatient
Insulin Cases: Inpatient and Outpatient Susan Cornell, BS, PharmD., CDE, FAPhA, FAADE Associate Director, Office of Experiential Education Associate Professor of Pharmacy Practice Midwestern University
More informationCase Study: Competitive exercise
Case Study: Competitive exercise 32 year-old cyclist Type 1 diabetes since age 15 Last HbA1 54 No complications and hypo aware On Humalog 8/8/8 and Levemir 15 Complains about significant hypoglycaemia
More informationLET S TALK INSULIN THE BASICS
LET S TALK INSULIN THE BASICS AUTHOR S DISCLOSURES Contracted for program development for Lifescan Canada Speaker for Lifescan, Lilly, BI, Consultant for Lilly, Janssen, Novo Nordisk, Lifescan Canada OBJECTIVES
More informationOpinion 18 December 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 LANTUS 100 units/ml, solution for injection in a vial B/1 vial of 10 ml (CIP: 34009 359 464 9 2)
More informationIntroduction. Methods
A New Perspective On A Difficult Discharge: Ensuring the newly diagnosed diabetic patient gets the proper prescriptions when it s time to go home. Ashley Carter, PGY 3 Introduction A hospitalized patient
More informationInsulin Initiation, titration & Insulin switch in the Primary Care-KISS
Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Rotorua GP CME 9 June 2012 Dr Kingsley Nirmalaraj FRACP Endocrinologist, BOPDHB & Suite 9, Promed House, Tenth Ave, Tauranga Linda
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationANGELA GINN-MEADOW RD LDN CDE
DIABETES DRUGS & TRENDS MADE SIMPLE PHARMD TO RD ANGELA GINN-MEADOW RD LDN CDE OBJECTIVES At the end of this presentation, participants should be able to: Evaluate the emerging role of GLP-1 Agonists for
More informationInsulin 10/11/17. Disclosures. Objectives. Speaker and Consultant for Jansen and Healthscripts Speaker and Consultant for Boehringer Ingelheim (BI)
Insulin The What, When, Where, Who and Why Disclosures Speaker and Consultant for Jansen and Healthscripts Speaker and Consultant for Boehringer Ingelheim (BI) Objectives Define background and history
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More information!"#$%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!(((
!"#%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!((( 26%5&"7%'( At the end of this presentation, participants should be able to: Evaluate the emerging role of GLP-1 Agonists for weight loss Understand
More information